Current Report Filing (8-k)
July 12 2022 - 4:32PM
Edgar (US Regulatory)
0001292519
false
0001292519
2022-07-07
2022-07-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
July 7, 2022
Date
of Report (Date of earliest event reported)
INVIVO THERAPEUTICS HOLDINGS CORP.
(Exact Name of Registrant as Specified in
Charter)
Nevada |
001-37350 |
36-4528166 |
(State or Other |
(Commission File Number) |
(IRS Employer |
Jurisdiction of Incorporation) |
|
Identification No.) |
One Kendall Square, Suite B14402
Cambridge, Massachusetts
02139
(Address of Principal Executive Offices)
(Zip Code)
(617) 863-5500
(Registrant’s telephone
number, including area code)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant
to Section 12(b) of the Act:
Title of each class |
|
Trading symbol(s) |
|
Name of each exchange on which
registered |
Common
Stock, $0.00001 par value per share |
|
NVIV |
|
The Nasdaq Capital Market |
Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ¨
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On
July 7, 2022, the Board of Directors (the “Board”) of InVivo Therapeutics Holdings Corp. (the “Company”)
amended the Company’s Transaction Incentive Plan, which was previously approved by the Board on August 11, 2021 (the “Amended
Plan”). The Board extended the term of the Amended Plan by one (1) year through August 11, 2023, subject to the right
of the Board to extend the effectiveness of the Amended Plan at its sole discretion. Under the Amended Plan, eligible participants, including
each of Dr. Richard Toselli, our Chief Executive Officer, and Richard Christopher, our Chief Financial Officer, are entitled to receive
a predefined percentage of the Transaction Consideration (as defined in the Amended Plan) paid in connection with a Company Acquisition
(as defined in the Amended Plan), minus the value of vested equity held by such participant. Pursuant to the Amended Plan, the percentage
interests for Dr. Toselli and Mr. Christopher are set at 3.5% and 1.25%, respectively.
The
above description of the Amended Plan is qualified in its entirety by reference to the full text of the Amended Plan, a copy of which
is filed as Exhibit 10.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
INVIVO THERAPEUTICS HOLDINGS CORP. |
|
|
|
Date: July 12, 2022 |
By: |
/s/ Richard Toselli |
|
Name: |
Richard Toselli, M.D. |
|
Title: |
Chief Executive Officer |
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Mar 2024 to Apr 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Apr 2023 to Apr 2024